Design and Immunological Evaluation of a Hybrid Peptide as a Potent TLR2 Agonist by Structure-Based Virtual Screening.
Zhang. Lulu L; Wei. Xubiao X; Zhang. Rijun R; Mozdziak. Paul E PE; Si. Dayong D; Ahmad. Baseer B; Cheng. Qiang Q; Tong. Yucui Y
Key Findings
- LTPa, a hybrid of TP5 and a fragment of LL‑37, was identified as the strongest TLR2 agonist among six designs.
- In vitro and mouse studies showed LTPa reduced immunosuppression, increased immune organ indices, and enhanced dendritic cell maturation and cytokine production.
- The immunomodulatory effect is linked to TLR2 binding, formation of TLR2 clusters, and activation of the NF‑κB signaling pathway.
Practical Outcomes
- For now, LTPa is an experimental molecule that works in mice but has no human safety or dosage data. Biohackers should view it as a promising concept for future immune‑support strategies rather than a ready‑to‑use supplement. Monitoring further research may eventually inform protocols for immune health optimization.
Summary
Scientists created a new hybrid peptide called LTPa by mixing parts of two known immune‑boosting peptides (TP5 and LL‑37). In lab tests and in mice with a weakened immune system, LTPa activated a key immune sensor (TLR2), improved immune organ size, helped immune cells mature, and raised important immune signals. The work shows the peptide can fight immunosuppression in animals, but it’s still far from being a safe, proven supplement for people.
Abstract
Immunity is a versatile defensive response that is involved in protecting against disease by identifying and destroying self and non-self harmful substances. As a state of temporary or permanent immune dysfunction, immunosuppression can make an organism more susceptible to infection, organ injury, and cancer due to damage to the immune system. It has taken a long time to develop new immunomodulatory agents to prevent and treat immunosuppressive diseases. In recent years, Toll-like receptor 2 (TLR2) agonists have been reported to have profound effects on the immune system, and they are regarded as potent immunomodulatory candidates. TP5 and LL-37, the potent immunomodulatory agents, have been reported to produce a robust innate immune response by binding to TLR2. However, their development has been weakened by several concerns, such as potential cytotoxicity, weak physiological stability and poor immunomodulatory activity. To overcome these challenges, hybridization has been proposed. Therefore, six hybrid peptides (LTPa, LTPb, LTPc, TPLa, TPLb, and TPLc) were designed by combining the full-length TP5 with a characteristic fragment of LL-37 that included LL-37 (13-36), LL-37 (17-29), and LL-37 (13-31). LTPa, the most potent TLR2 agonist, was simply and effectively screened by molecular docking and <i>in vitro</i> experiments. Furthermore, the immunomodulatory effects of LTPa were confirmed by a CTX-immunosuppressed murine model, which demonstrated that LTPa successfully inhibit immunosuppression, increased immune organ indices, enhanced DC maturation, regulated T lymphocyte subsets, and increased cytokine and Ig contents. Our study also revealed that the immunomodulatory effects of LTPa are associated with binding to TLR2, forming TLR2 clusters, and activating the NF-κB signaling pathway.
Study Information
pubmed
2021
2021-02-11T00:00:00.000Z
10.3389/fcell.2021.620370
7
68